Summary

Japan Dry Eye Medication Market was valued at USD 232.26 Million in 2024 and is expected to reach USD 311.47 Million by 2030 with a CAGR of 4.97% during the forecast period. The Japan dry eye medication market is driven by several key factors. Increasing prevalence of dry eye disease, influenced by an aging population, lifestyle changes, and prolonged screen time, is a primary driver. The rise in digital device usage has exacerbated dry eye symptoms, creating a greater demand for effective treatments. Advances in pharmaceutical research have introduced innovative therapies, such as new lubricants, anti-inflammatory agents, and anti-allergic medications, enhancing treatment options. Growing awareness and improved diagnostics have led to earlier detection and better management of dry eye disease. The increasing availability of advanced drug delivery systems, such as sustained-release formulations, further supports market growth. Enhanced public awareness campaigns and educational efforts by healthcare professionals also contribute to the demand for dry eye medications, promoting proactive treatment and management.Key Market DriversRising Prevalence of Dry Eye DiseaseThe escalating prevalence of dry eye disease in Japan is a major driver of the dry eye medication market. Dry eye disease, characterized by insufficient tear production or poor tear quality, is becoming increasingly common in the country due to various lifestyle and environmental factors. One of the primary contributors to the rise in dry eye cases is Japan's aging population. As people age, tear production naturally declines, making older adults more susceptible to dry eye symptoms. This demographic shift significantly impacts the demand for dry eye treatments. According to a study titled, “Prevalence and Risk Factors of Dry Eye Disease in Japan: Koumi Study”, among a Japanese cohort, dry eye disease (DED) resulting in clinical diagnosis or severe symptoms is notably prevalent. Contact lens (CL) use emerged as a common risk factor for dry eye across both genders. Men with low body mass index (BMI) and hypertension (HT), as well as women with a history of myocardial infarction or angina and prolonged use of visual display terminals (VDTs), were particularly affected. Out of 3,294 eligible residents, 2,791 (85%) completed the questionnaire. The prevalence of clinically diagnosed DED or severe symptoms was higher in women (21.6%; 95% confidence interval [CI], 19.5–23.9) compared to men (12.5%; 95% CI, 10.7–14.5; P<0.001). In men, low BMI (odds ratio [OR], 2.07; 95% CI, 0.98–4.39), CL use (OR, 3.84; 95% CI, 1.46–10.10), and hypertension (OR, 1.39; 95% CI, 0.94–2.06) were identified as risk factors for DED. For women, risk factors included VDT use (OR, 2.33; 95% CI, 1.12–4.85), CL use (OR, 3.61; 95% CI, 2.13–6.10), and myocardial infarction or angina (OR, 2.64; 95% CI, 1.51–4.62), while high BMI acted as a preventive factor (OR, 0.69; 95% CI, 0.48–1.01).Modern lifestyle changes play a substantial role in the growing incidence of dry eye disease. The extensive use of digital devices, such as smartphones, computers, and tablets, has become ubiquitous in Japan. Prolonged screen time is known to reduce blink rates, which in turn decreases the spread of tears across the ocular surface and leads to increased dryness. This trend is further compounded by the high pace of work and daily life in urban areas, where individuals often spend long hours in front of screens, exacerbating their dry eye symptoms. Environmental factors also contribute to the increasing prevalence of dry eye disease. The frequent use of air conditioning and heating systems in both personal and professional environments creates a dry indoor atmosphere. These systems can reduce the humidity levels in the air, which exacerbates ocular surface dryness and contributes to the discomfort associated with dry eye disease. The combination of these environmental factors with prolonged exposure to digital screens creates a challenging situation for individuals suffering from dry eye, increasing their need for effective therapeutic solutions.The growing awareness of dry eye disease and its impact on quality of life is driving market demand for effective treatments. As more individuals recognize the symptoms and seek relief from the discomfort associated with dry eye, the market for dry eye medications is expanding. This increased awareness is partly fueled by public health campaigns and advancements in diagnostic technologies that allow for earlier and more accurate detection of dry eye disease. Enhanced diagnostics, such as improved tear break-up time tests and advanced ocular surface assessments, enable healthcare providers to identify and manage dry eye more effectively, further stimulating demand for therapeutic options. Pharmaceutical companies are responding to this rising demand by developing and offering a wider range of dry eye treatments tailored to the specific needs of Japanese patients. Innovations in medication formulations, drug delivery systems, and therapeutic approaches are being introduced to address various aspects of dry eye disease. For instance, the development of advanced artificial tears that provide longer-lasting relief and new anti-inflammatory drugs that target underlying causes of dry eye are contributing to market growth. The increasing availability of prescription treatments, such as anti-VEGF therapies and immunomodulatory agents, offers patients more comprehensive options for managing their condition.Advancements in Pharmaceutical ResearchAdvancements in pharmaceutical research have played a pivotal role in shaping the growth of the dry eye medication market in Japan. Recent innovations in therapeutic approaches have significantly enhanced the management of dry eye disease, addressing both its symptoms and underlying causes with greater precision and effectiveness.One of the major advancements in the field is the development of new classes of medications that target specific aspects of dry eye disease. Anti-inflammatory agents, for example, have been introduced to address the chronic inflammation of the ocular surface, a key factor in the pathophysiology of dry eye. These medications work by reducing inflammation, which not only alleviates symptoms but also helps to prevent further damage to the ocular surface. The efficacy of these agents represents a significant improvement over traditional treatments, making them a valuable addition to the therapeutic arsenal for managing dry eye disease.Advancements in drug delivery systems have markedly improved the efficacy and convenience of dry eye treatments. Sustained-release formulations, which allow for the gradual release of medication over an extended period, provide longer-lasting relief from dry eye symptoms. This approach reduces the frequency of application and enhances patient compliance. Similarly, liposomal eye drops have been developed to improve the stability and effectiveness of treatment. These drops encapsulate the therapeutic agents in lipid layers, enhancing their ability to penetrate the ocular surface and deliver targeted relief. Such innovations in drug delivery not only improve the therapeutic outcomes but also offer a more user-friendly experience for patients. The development of new and improved formulations has also contributed to better patient compliance and overall outcomes. Advanced formulations are designed to address specific symptoms of dry eye, such as discomfort and dryness, more effectively than previous treatments. For example, newer artificial tear products may include additional components that mimic natural tear film properties, providing more comprehensive relief. These innovations are aimed at meeting the diverse needs of patients and improving their quality of life.Availability of Advanced Drug Delivery SystemsThe development of advanced drug delivery systems has profoundly impacted the dry eye medication market in Japan, driving significant changes in how treatments are administered and experienced by patients. Innovations in drug delivery technologies have ushered in a new era of therapeutic options that enhance both the effectiveness and convenience of managing dry eye disease. One of the key advancements is the introduction of sustained-release formulations. These systems are designed to release medication gradually over an extended period, which helps maintain therapeutic levels in the ocular surface with fewer applications. This continuous release reduces the need for frequent dosing, which not only improves patient adherence but also ensures more consistent symptom relief. By minimizing the frequency of application, sustained-release formulations address one of the common barriers to treatment compliance, making them an attractive option for both patients and healthcare providers.Hydrogels represent another significant innovation in drug delivery for dry eye treatments. These are water-absorbing polymers that can hold and slowly release therapeutic agents over time. Hydrogels offer several advantages, including enhanced comfort and improved retention on the ocular surface. Their ability to provide a moist environment helps in stabilizing the tear film, which is crucial for effective dry eye management. The use of hydrogels can significantly improve the patient experience by reducing the discomfort often associated with traditional eye drops and providing longer-lasting relief. Liposomal eye drops have also emerged as a major breakthrough in the field. These drops incorporate medications into tiny lipid-based vesicles, which protect the active ingredients and facilitate their delivery to the ocular surface. The liposomes help in enhancing the stability and bioavailability of the therapeutic agents, making them more effective at treating dry eye symptoms. Liposomal formulations can mimic the natural tear film more closely, which improves their ability to lubricate and protect the eye. This innovation not only enhances the efficacy of the treatment but also contributes to a better overall patient experience.Support from Healthcare Policies and RegulationsSupport from healthcare policies and regulations plays a vital role in driving the Japan dry eye medication market. Government initiatives and healthcare policies aimed at improving the management and treatment of dry eye disease contribute to the market's growth. Reimbursement policies, coverage of dry eye medications under national health insurance, and support for research and development in the field enhance access to treatment and foster innovation. Regulatory agencies in Japan are actively involved in approving new therapies and ensuring their safety and efficacy. The supportive regulatory environment and healthcare policies facilitate the introduction and adoption of new dry eye medications, driving market expansion. The alignment of healthcare policies with the needs of patients and advancements in therapeutic options supports the growth of the dry eye medication market in Japan.Key Market ChallengesLimited Awareness and UnderdiagnosisLimited awareness and underdiagnosis of dry eye disease present another significant challenge for the Japan dry eye medication market. Despite increasing public awareness campaigns, many patients with dry eye symptoms may not recognize the condition or may attribute their symptoms to other causes. This can lead to delayed diagnosis and treatment, affecting the overall effectiveness of therapeutic interventions. Healthcare providers may not always have the most up-to-date knowledge of the latest diagnostic and treatment options, leading to underdiagnosis or suboptimal management of dry eye disease. The lack of standardized diagnostic protocols and insufficient training for healthcare professionals can further exacerbate the issue. Addressing these gaps in awareness and diagnosis is crucial for improving patient outcomes and driving market growth.Competition from Over-the-Counter ProductsThe presence of a wide range of over-the-counter (OTC) products for dry eye relief presents a challenge to the Japan dry eye medication market. Many patients may choose OTC remedies, such as artificial tears and lubricating eye drops, over prescription medications due to their lower cost and ease of availability. While these OTC products can provide temporary relief, they may not address the underlying causes of dry eye disease or offer the same level of efficacy as prescription treatments. The competitive landscape created by OTC products can impact the market share of prescription medications and create barriers to market growth. To counteract this challenge, pharmaceutical companies must differentiate their products through superior efficacy, advanced formulations, and evidence-based benefits to encourage patients and healthcare providers to opt for prescription therapies.Key Market TrendsEnhanced Diagnostic TechnologiesThe advancement of diagnostic technologies has significantly impacted the Japan dry eye medication market, ushering in a new era of precision in diagnosing and managing dry eye disease. Enhanced diagnostic tools have revolutionized the way healthcare providers detect, evaluate, and treat this prevalent condition, leading to a more effective and personalized approach to patient care.Optical Coherence Tomography (OCT) represents a major leap forward in dry eye diagnostics. OCT is a non-invasive imaging technique that provides high-resolution cross-sectional images of the ocular structures, particularly the retina and the cornea. This advanced imaging technology allows clinicians to assess the thickness and integrity of the corneal epithelium and other key layers, which are crucial for understanding the severity of dry eye disease. By visualizing changes in the ocular surface at a microscopic level, OCT enables early detection of pathological alterations associated with dry eye. This capability is instrumental in diagnosing the condition before it progresses to more severe stages, thus allowing for earlier and potentially more effective intervention. Tear Break-Up Time (TBUT) tests are another essential advancement in dry eye diagnostics. TBUT measures the stability of the tear film by evaluating how quickly tears evaporate from the surface of the eye. This test is straightforward yet highly effective in determining the presence of dry eye symptoms and assessing the functional integrity of the tear film. Advances in TBUT testing have led to more precise and reliable measurements, helping clinicians diagnose dry eye more accurately. The ability to obtain detailed information about tear film stability enhances the diagnostic process and supports the development of tailored treatment plans that address the specific needs of each patient.Increasing Screen Time and Digital Device UsageThe widespread use of digital devices and the accompanying increase in screen time have significantly impacted the prevalence and management of dry eye disease in Japan, contributing to a burgeoning market for dry eye medications. As technology continues to evolve, modern lifestyles have increasingly revolved around extensive use of computers, smartphones, and tablets. This constant engagement with digital screens has introduced a host of new challenges for eye health, prominently affecting the ocular surface and exacerbating dry eye symptoms. The phenomenon of "digital eye strain" or "computer vision syndrome" has become a major concern as individuals spend extended periods interacting with screens. The primary issue stems from the reduction in blink frequency that occurs when people focus on digital devices. Blinking is a critical physiological process that helps to spread tears evenly across the ocular surface, maintaining moisture and removing debris. However, when people are deeply engrossed in screen activities, their blink rate significantly decreases. This decreased frequency of blinking leads to an inadequate distribution of tears, which in turn contributes to an increase in ocular surface dryness and discomfort. According to a 2021 survey in Japan revealed that men in their twenties averaged 206 minutes per day on their smartphones. In contrast, men over the age of 40 spent more time watching television than using their smartphones, a trend not observed among younger generations.Prolonged screen use often results in the exposure of the eyes to harsh lighting conditions, such as bright screens and high-contrast displays. These factors can exacerbate the drying effect on the eyes and further aggravate symptoms of dry eye disease. The combination of reduced blinking and environmental factors creates a perfect storm for the development and worsening of dry eye symptoms, including irritation, redness, and a gritty sensation in the eyes. The rising incidence of dry eye disease, driven by increased digital device usage, has spurred a significant demand for effective treatments. Patients experiencing digital eye strain seek relief from the discomfort associated with prolonged screen exposure, leading to a heightened interest in dry eye medications. As awareness of the impact of digital screen time on eye health grows, both healthcare professionals and patients are increasingly recognizing the need for effective therapeutic solutions.Segmental InsightsDisease Type InsightsBased on the Disease Type, Aqueous Dry Eye Syndrome was currently the dominated form of dry eye disease. This condition is characterized by a deficiency in the production of tears, which leads to insufficient moisture on the ocular surface. Aqueous dry eye syndrome occurs when the lacrimal glands, responsible for producing the aqueous component of tears, are not functioning properly. This results in symptoms such as dryness, irritation, and a feeling of grittiness in the eyes. Several factors contribute to the predominance of aqueous dry eye syndrome in Japan. One of the primary drivers is the aging population, as the incidence of aqueous dry eye syndrome increases with age. The natural aging process leads to a gradual decline in tear production, making older adults more susceptible to this type of dry eye disease. With Japan having one of the world’s most rapidly aging populations, the prevalence of aqueous dry eye syndrome has consequently risen. Another significant factor is the impact of environmental and lifestyle changes. The urbanized and technologically driven lifestyle in Japan, characterized by long hours spent in front of digital screens, contributes to the exacerbation of aqueous dry eye symptoms. Prolonged screen use reduces blinking rates, which in turn decreases tear distribution and exacerbates dryness. Exposure to air conditioning and heating systems in both personal and professional environments further aggravates aqueous dry eye syndrome by drying out the ocular surface.The treatment landscape for aqueous dry eye syndrome is heavily influenced by the development and availability of various therapeutic options. Medications such as artificial tears, anti-inflammatory agents, and other tear substitutes are commonly used to manage the symptoms associated with this condition. Pharmaceutical companies have developed a range of products specifically targeting aqueous dry eye syndrome, reflecting its dominant position in the market. Advances in drug formulations, including sustained-release and preservative-free options, have enhanced the effectiveness and patient acceptance of these treatments. In addition, the prevalence of aqueous dry eye syndrome is supported by the high rates of autoimmune conditions such as Sjögren’s syndrome in Japan. Sjögren’s syndrome is a chronic autoimmune disease that primarily affects the lacrimal and salivary glands, leading to significant reductions in tear production and salivation. As autoimmune disorders are more prevalent among the aging population, their impact on tear production further contributes to the dominance of aqueous dry eye syndrome.Drug Type InsightsBased on Drug Type, lubricant eye drops was currently the dominated therapy. Lubricant eye drops, often referred to as artificial tears, are extensively used to manage symptoms of dry eye disease by providing temporary relief through lubrication of the ocular surface. The prevalence of dry eye disease in Japan, exacerbated by lifestyle factors and an aging population, has driven the high demand for lubricant eye drops. These drops are designed to mimic natural tears and alleviate symptoms such as dryness, irritation, and a gritty sensation in the eyes. Their widespread use is attributed to their effectiveness, accessibility, and the ease with which they can be administered by patients. Lubricant eye drops come in various formulations, including those with different viscosities and preservative-free options. This variety allows for tailored treatments based on individual patient needs and preferences. The choice between different types of lubricant eye drops often depends on factors such as the severity of symptoms, frequency of application, and potential sensitivity to preservatives.One of the key reasons for the dominance of lubricant eye drops in the market is their immediate efficacy in alleviating dry eye symptoms. They provide quick relief by creating a film over the ocular surface, which helps to stabilize the tear film and reduce evaporation. This immediate effect makes them a popular choice among patients seeking quick and effective relief from dry eye discomfort. Lubricant eye drops are widely available both over-the-counter and through prescription, contributing to their dominance in the market. Their availability in pharmacies, online stores, and healthcare facilities ensures that patients have easy access to these medications, further driving their use. The convenience and affordability of lubricant eye drops make them a first-line treatment for many individuals experiencing dry eye symptoms. The continued advancements in the formulation of lubricant eye drops also play a significant role in their market dominance. Innovations such as sustained-release formulations and improved delivery systems enhance the effectiveness and patient compliance. For instance, sustained-release formulations reduce the frequency of application required, which can be particularly beneficial for patients with moderate to severe dry eye disease.Regional InsightsIn the Japan dry eye medication market, the Kanto region stands out as the dominant area. The Kanto region, which includes major metropolitan areas such as Tokyo and Yokohama, is a central hub of economic activity, healthcare infrastructure, and population density in Japan. This concentration of population and resources plays a pivotal role in driving the demand for dry eye medications. The Kanto region's prominence in the dry eye medication market can be attributed to several factors. The high population density in urban centers like Tokyo contributes to a significant number of individuals affected by dry eye disease. The fast-paced lifestyle and extended screen time associated with city living exacerbate the prevalence of dry eye symptoms. As a result, there is a higher demand for effective treatments and therapeutic options in these densely populated areas.The Kanto region is home to some of Japan's leading medical institutions, research facilities, and pharmaceutical companies. This concentration of healthcare infrastructure fosters innovation and provides access to advanced diagnostic and therapeutic technologies. The presence of major research institutions and clinical centers in the Kanto region facilitates the development and distribution of cutting-edge dry eye treatments, further boosting the market's growth. The region's economic strength also contributes to its dominance in the dry eye medication market. With a robust economy and higher disposable incomes, residents in the Kanto region have greater access to healthcare services and are more likely to seek out and afford specialized treatments for dry eye disease. The availability of premium and advanced dry eye medications is more prevalent in this economically prosperous area, leading to increased market activity.The Kanto region benefits from its strategic location as a transportation and distribution hub. This accessibility ensures efficient distribution of dry eye medications across the region, making it easier for patients to obtain necessary treatments. The region's well-developed infrastructure supports a steady supply of medications, contributing to its dominant position in the market. The high level of awareness and education about dry eye disease in the Kanto region also plays a significant role. Public awareness campaigns and educational initiatives about the importance of managing dry eye symptoms and seeking timely treatment are more prominent in this area. This heightened awareness translates into a greater demand for dry eye medications and proactive management of the condition.Key Market Players• AbbVie GK• Novartis Pharma K.K.• Santen Pharmaceutical Co., Ltd.• Janssen Pharmaceuticals K.K.• Senju Pharmaceutical Co., Ltd.• Taisho Pharmaceutical Co., Ltd• Otsuka Pharmaceutical Co., Ltd.• Sun Pharma Japan Limited• Asahi Kasei Pharma Corporation• Kyowa Pharmaceutical Industry Co., Ltd.Report Scope:In this report, the Japan Dry Eye Medication Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:• Japan Dry Eye Medication Market, By Disease Type:o Evaporative Dry Eye Syndromeo Aqueous Dry Eye Syndrome• Japan Dry Eye Medication Market, By Drug Type:o Anti-inflammatory Drugso Lubricant Eye Dropso Autologous Serum Eye Drops• Japan Dry Eye Medication Market, By Product:o Liquid Dropso Gelo Liquid Wipeso Eye Ointmento Others• Japan Dry Eye Medication Market, By Distribution Channel:o Hospital Pharmacieso Retail Pharmacieso Online Pharmacies• Japan Dry Eye Medication Market, By Region:o Hokkaidoo Tohokuo Kantoo Chubuo Kansaio Chugokuo Shikokuo KyushuCompetitive LandscapeCompany Profiles: Detailed analysis of the major companies present in the Japan Dry Eye Medication Market.Available Customizations:Japan Dry Eye Medication Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:Company Information• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Japan Dry Eye Medication Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Disease Type (Evaporative Dry Eye Syndrome, Aqueous Dry Eye Syndrome)
5.2.2. By Drug Type (Anti-inflammatory Drugs, Lubricant Eye Drops, Autologous Serum Eye Drops)
5.2.3. By Product (Liquid Drops, Gel, Liquid Wipes, Eye Ointment, and Others)
5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Market Map
6. Hokkaido Dry Eye Medication Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Disease Type
6.2.2. By Drug Type
6.2.3. By Product
6.2.4. By Distribution Channel
7. Tohoku Dry Eye Medication Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Disease Type
7.2.2. By Drug Type
7.2.3. By Product
7.2.4. By Distribution Channel
8. Kanto Dry Eye Medication Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Disease Type
8.2.2. By Drug Type
8.2.3. By Product
8.2.4. By Distribution Channel
9. Chubu Dry Eye Medication Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Disease Type
9.2.2. By Drug Type
9.2.3. By Product
9.2.4. By Distribution Channel
10. Kansai Dry Eye Medication Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Disease Type
10.2.2. By Drug Type
10.2.3. By Product
10.2.4. By Distribution Channel
11. Chugoku Dry Eye Medication Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Disease Type
11.2.2. By Drug Type
11.2.3. By Product
11.2.4. By Distribution Channel
12. Shikoku Dry Eye Medication Market Outlook
12.1. Market Size & Forecast
12.1.1. By Value
12.2. Market Share & Forecast
12.2.1. By Disease Type
12.2.2. By Drug Type
12.2.3. By Product
12.2.4. By Distribution Channel
13. Kyushu Dry Eye Medication Market Outlook
13.1. Market Size & Forecast
13.1.1. By Value
13.2. Market Share & Forecast
13.2.1. By Disease Type
13.2.2. By Drug Type
13.2.3. By Product
13.2.4. By Distribution Channel
14. Market Dynamics
14.1. Drivers
14.2. Challenges
15. Market Trends & Developments
15.1. Merger & Acquisition (If Any)
15.2. Product Launches (If Any)
15.3. Recent Developments
16. Japan Dry Eye Medication Market: SWOT Analysis
17. Porter’s Five Forces Analysis
17.1. Competition in the Industry
17.2. Potential of New Entrants
17.3. Power of Suppliers
17.4. Power of Customers
17.5. Threat of Substitute Products
18. Competitive Landscape
18.1. AbbVie GK
18.1.1. Business Overview
18.1.2. Company Snapshot
18.1.3. Products & Services
18.1.4. Financials (As Reported)
18.1.5. Recent Developments
18.1.6. Key Personnel Details
18.1.7. SWOT Analysis
18.2. Novartis Pharma K.K.
18.3. Santen Pharmaceutical Co., Ltd.
18.4. Janssen Pharmaceuticals K.K.
18.5. Senju Pharmaceutical Co., Ltd.
18.6. Taisho Pharmaceutical Co., Ltd
18.7. Otsuka Pharmaceutical Co., Ltd.
18.8. Sun Pharma Japan Limited
18.9. Asahi Kasei Pharma Corporation
18.10. Kyowa Pharmaceutical Industry Co., Ltd.
19. Strategic Recommendations
20. About Us & Disclaimer